- Home
- REE vs BLRX Comparison
REE vs BLRX Comparison
Compare REE & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- BLRX
- Stock Information
- Founded
- REE 2011
- BLRX 2003
- Country
- REE Israel
- BLRX Israel
- Employees
- REE N/A
- BLRX N/A
- Industry
- REE Auto Manufacturing
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- REE Consumer Discretionary
- BLRX Health Care
- Exchange
- REE Nasdaq
- BLRX Nasdaq
- Market Cap
- REE 18.5M
- BLRX 17.2M
- IPO Year
- REE N/A
- BLRX 2011
- Fundamental
- Price
- REE $0.72
- BLRX $3.75
- Analyst Decision
- REE Strong Buy
- BLRX Strong Buy
- Analyst Count
- REE 2
- BLRX 2
- Target Price
- REE $11.75
- BLRX $19.00
- AVG Volume (30 Days)
- REE 66.5K
- BLRX 34.3K
- Earning Date
- REE 09-16-2025
- BLRX 08-14-2025
- Dividend Yield
- REE N/A
- BLRX N/A
- EPS Growth
- REE N/A
- BLRX N/A
- EPS
- REE N/A
- BLRX N/A
- Revenue
- REE $183,000.00
- BLRX $17,251,000.00
- Revenue This Year
- REE $6,661.20
- BLRX N/A
- Revenue Next Year
- REE $2,240.01
- BLRX N/A
- P/E Ratio
- REE N/A
- BLRX N/A
- Revenue Growth
- REE N/A
- BLRX 1.19
- 52 Week Low
- REE $0.53
- BLRX $2.30
- 52 Week High
- REE $11.72
- BLRX $26.80
- Technical
- Relative Strength Index (RSI)
- REE 53.85
- BLRX 47.46
- Support Level
- REE $0.65
- BLRX $3.42
- Resistance Level
- REE $0.75
- BLRX $4.11
- Average True Range (ATR)
- REE 0.04
- BLRX 0.27
- MACD
- REE 0.01
- BLRX 0.05
- Stochastic Oscillator
- REE 61.33
- BLRX 35.11
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.